flunixin meglumine (Banamine)

08/01/2017 - "The objective of this study was to evaluate the effect of flunixin meglumine treatment on lameness pain in dairy cows. "
06/21/2023 - "Transdermal Flunixin Meglumine as a Pain Relief in Donkeys: A Pharmacokinetics Pilot Study."
01/01/2023 - "Results show that flunixin meglumine was effective at reducing pain-related behaviours when given at the time of disbudding."
01/01/2021 - "Flunixin meglumine was the most effective treatment at reducing ocular pain in the horse. "
01/01/2021 - "There were significantly lower pain scores (P = .01) in the flunixin meglumine group when compared with those recorded in the control group during the first 46 hours. "

05/01/2013 - "Flunixin meglumine was significantly more effective at ameliorating fever compared with EP. "
05/01/2009 - "Effects of flunixin meglumine on pyrexia and bioenergetic variables in postparturient dairy cows."
05/01/2002 - "One mare had a fever for 24 hours' postoperatively; this responded to a single dose of flunixin meglumine. "
01/01/2020 - "Flunixin meglumine (FM) is a non-steroidal anti-inflammatory drug currently approved in the United States for pyrexia in swine and lameness pain in cattle. "
01/01/2004 - "Flunixin meglumine decreased rectal temperature, whereas isoflupredone did not; however, it has not been established that reduction of fever is beneficial to cows with naturally occurring mastitis."

07/01/1987 - "Seemingly, flunixin meglumine helped to maintain acceptable cardiovascular function and tissue perfusion during endotoxemia. "
12/01/2020 - "Initially a dose of flunixin meglumine was administrated intravenous to prevent an endotoxemia. "
01/01/1997 - "Treatments used to attempt to prevent development of endotoxemia or to treat horses with endotoxemia included i.v. fluids and administration of broad-spectrum antimicrobials and flunixin meglumine."
07/01/1988 - "Effects of flunixin meglumine in dogs following experimentally induced endotoxemia."
05/01/2009 - "Signs of endotoxemia (P = 0.30), hypoxia (P = 0.89), flunixin meglumine administration (P = 0.13), mucous membrane color at the time of presentation (P = 0.82) and capillary refill time (P = 0.76) were not associated with pregnancy outcome. "

12/01/2017 - "The obtained results indicate the selectively potent anti-inflammatory effect of flunixin meglumine on the production of pro-inflammatory cytokines in pneumonic buffalo calves and highlight the efficacy of flunixin meglumine in the treatment of bronchopneumonia in buffalo calves when used in combination with tulathromycin."
01/01/2003 - "These results suggest that the combination of meloxicam with an antibiotic or flunixin meglumine with an antibiotic which does not exert an immunosuppressive influence on the organism of calves suffering from enzootic bronchopneumonia is equally effective in the treatment of calves and superior to the antibiotic alone."
01/01/2003 - "The study was performed on 18 Black-and-White Lowland Breed calves with clinical signs of enzootic bronchopneumonia divided into three groups and respectively treated with oxytetracycline and meloxicam--Group I (9 animals); oxytetracycline and flunixin meglumine--Group II (3 animals); and oxytetracycline only--Group III (6 animals--control). "
01/01/2003 - "A comparative study of the effects of meloxicam and flunixin meglumine (NSAIDs) as adjunctive therapy on interferon and tumor necrosis factor production in calves suffering from enzootic bronchopneumonia."

01/04/1986 - "In a double blind trial the calves were injected intravenously with either flunixin meglumine (2 mg/kg body weight) or with a placebo. "
02/01/2014 - "Effect of body weight on the pharmacokinetics of flunixin meglumine in miniature horses and quarter horses."
11/01/1999 - "Blood samples were collected at time zero (before) and 5, 10, 15, 30, and 45 minutes, and at 1, 1.25, 1.5, 1.75, 2, 2.5, 2.75, 3, 3.5, 4, 4.5, 5, 5.5, 6, and 8 hours after i.v. administration of a bolus of flunixin meglumine (1.1 mg/kg of body weight). "
01/01/1993 - "Following base recordings of isthmic intraluminal pressure, the gilts were treated with 2.2 mg flunixin meglumine (FM) per kg body weight. "
01/01/1988 - "Group-1 calves were untreated, group-2 calves were pretreated with a low dose of flunixin meglumine (1.1 mg/kg of body weight), and group-3 calves were pretreated with a high dose of flunixin meglumine (4.4 mg/kg). "